×
About 4,738 results

ALLMedicine™ Hyperuricemia Center

Research & Reviews  1,510 results

Genetic risk of hyperuricemia in hypertensive patients associated with antihypertensive...
https://doi.org/10.1111/cge.14110
Clinical Genetics; Chen Y, Yang Y et. al.

Jan 14th, 2022 - Elevated serum uric acid (UA) level has been shown to be influenced by multiple genetic variants, but it remains uncertain how UA-associated variants differ in their influence on hyperuricemia risk in people taking antihypertensive drugs. We exami...

A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia
https://clinicaltrials.gov/ct2/show/NCT03934099

Jan 13th, 2022 - The aim of this 12-week randomized multicenter double-blind parallel group placebo-controlled dose finding study is to assess the efficacy and safety of three different doses of LC350189 in subjects with hyperuricemia and a diagnosis of gout.

Genetic association studies of the progression from hyperuricemia to gout.
https://doi.org/10.1093/rheumatology/keac011
Rheumatology (Oxford, England); Sumpter NA, Takei R et. al.

Jan 13th, 2022 - Genetic association studies of the progression from hyperuricemia to gout.|2022|Sumpter NA,Takei R,Leask MP,Reynolds RJ,Merriman TR,|

see more →

Drugs  186 results see all →

Clinicaltrials.gov  47 results

A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia
https://clinicaltrials.gov/ct2/show/NCT03934099

Jan 13th, 2022 - The aim of this 12-week randomized multicenter double-blind parallel group placebo-controlled dose finding study is to assess the efficacy and safety of three different doses of LC350189 in subjects with hyperuricemia and a diagnosis of gout.

Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease
https://clinicaltrials.gov/ct2/show/NCT04987294

Dec 6th, 2021 - This is a randomized, double-blind, placebo-controlled parallel group, multi-center phase II clinical study or orally administered ALLN-346 in subjects with hyperuricemia, gout and mild to moderate chronic kidney disease over a two-week period. Su...

Placebo Controlled, Dose Escalation Study to Evaluate Safety, Pharmacokinetics & Efficacy of SAP-001 in Gout Patients
https://clinicaltrials.gov/ct2/show/NCT03857165

Oct 14th, 2021 - A total of 24 eligible adult subjects will be randomized in a 3:1 randomization ratio into two blinded treatment groups in the three dose cohorts with matching placebo arm. The duration of the observation would be 5 days for each subject with a si...

Acute Kidney Injury After Craniocerebral Operation
https://clinicaltrials.gov/ct2/show/NCT03789747

Aug 5th, 2021 - The study included consecutive adult patients who underwent craniotomy and admitted into intensive care unit (ICU) between January 2017 and December 2018. Patients with congenital renal abnormalities or with stages 4 and 5 chronic kidney disease (...

Crossover Clinical Trial, Randomized, Double Blind, Placebo Controlled Trial
https://clinicaltrials.gov/ct2/show/NCT04983160

Jul 30th, 2021 - The purpose of this study is to determine the effect of inhibiting xanthine oxidase with allopurinol in patients with chronic kidney disease in asymptomatic hyperuricemia endothelial injury and vascular repair mechanisms, evaluating the plasma con...

see more →

News  152 results

Another Study Confirms Gout Benefit With SGLT2 Inhibitors
https://www.medpagetoday.com/endocrinology/diabetes/95777

Nov 19th, 2021 - Patients with type 2 diabetes taking sodium-glucose cotransporter-2 (SGLT2) inhibitors saw a lower risk for gout, a Taiwanese cohort study found. Compared with patients taking DPP-4 inhibitors, those on an SGLT2 inhibitor had an 11% reduced risk f...

New Jardiance Indication? Bariatric Surgery for NASH; ICER Reviews Tirzepatide
https://www.medpagetoday.com/endocrinology/generalendocrinology/95628

Nov 14th, 2021 - The FDA accepted a supplemental new drug application for empagliflozin (Jardiance) as a treatment for heart failure independent of left ventricular ejection fraction in patients with or without diabetes based on the phase III EMPEROR-Preserved tri...

Acalabrutinib Elicits Early Activity in a Japanese Population With B-Cell Malignancies
https://www.onclive.com/view/acalabrutinib-elicits-early-activity-in-a-japanese-population-with-b-cell-malignancies

May 12th, 2021 - Acalabrutinib (Calquence) elicited early antitumor activity with acceptable tolerability in a population of Japanese patients with relapsed/refractory B-cell malignancies, according to the results of a phase 1 study (NCT03198650) published in Canc...

Rolling Submission Completed for Surufatinib in Advanced Neuroendocrine Tumors
https://www.onclive.com/view/rolling-submission-completed-for-surufatinib-in-advanced-neuroendocrine-tumors

May 3rd, 2021 - The rolling submission of a new drug application (NDA) to the FDA for surufatinib for the treatment of patients with pancreatic and non-pancreatic neuroendocrine tumors (NETs) has been completed, according to an announcement from Hutchinson China ...

New Gout Guidelines: Primary Care Pointers
https://www.medscape.com/viewarticle/945951

Mar 2nd, 2021 - This transcript has been edited for clarity. I'm Dr Neil Skolnik. Today we are going to talk about the 2020 American College of Rheumatology Guideline for the Management of Gout and get some really clear evidence-based guidance about treating gout...

see more →